Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes

• Objective: To study the effects and serum levels of glibenclamide (Gb) and its active metabolites in patients on chronic Gb medication on different daily doses. Material and methods: Fifty patients with type 2 diabetes on regular Gb therapy (1.75-14.0 mg daily). Blood samples were taken immediately before and 90 min after regular Gb intake. A standardized breakfast was served 30 min after drug intake. Serum insulin and proinsulin levels were determined by ELISA methods without cross-reactivities. Serum drug levels were determined by HPLC. Fischer's Rto Z-test (correlation coefficients) and paired Student t-tests were used when comparing values within the entire group and unpaired non-parametric Mann-Whitney tests were used when comparing high and low dose levels. A p-value <0.05 was considered significant. Results: There were significant correlations between daily Gb dose, on the one hand, and, on the other, HbAl(c) (r=0.55), -insulin (r=-0.59) and Delta -proinsulin (r=-0.52) levels. Significant correlations between Gb therapy duration and insulin (r=-0.40) and proinsulin (r=-0.34) secretion and between Gb dose and ratio proinsulin/insulin (RPI) at both time points (r=0.32 and 0.30) were also found. The RPI was lower after Gb intake. In patients on greater than or equal to 10.5 mg steady state serum metabolite levels (Ml and Ml + M2) were higher (29(0-120) and 33 (0-120) ng/ml) than those of Gb itself (18(0-64) ng/ml). A great inter-subject variability in Gb levels at both time points was seen. Conclusions: Our results indicate that, in patients on chronic medication, Gb is capable of stimulating both insulin and proinsulin secretion; the effect on insulin release is relatively greater. The effect was more pronounced in patients on a low Gb dose, either because of less impaired beta -cells in those receiving low doses, or due to reduced sulphonylurea sensitivity in those on high dosage (down-regulation). In patients on a daily dose of 10.5 mg or more, serum metabolite levels of clinical relevance were demonstrated; the metabolites may contribute to hypoglycaemic events.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Nyckelord

sulphonylurea

insulin

proinsulin

glibenclamide

metabolites

Publikations- och innehållstyp

art (ämneskategori)

ref (ämneskategori)